Sulfinpyrazone
| Clinical data | |
|---|---|
| Trade names | Anturan, Anturane, Apo-sulfinpyrazone |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682339 |
| Routes of administration | By mouth intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 98–99% |
| Metabolism | liver |
| Excretion | kidney |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.325 Edit this at Wikidata |
| Chemical and physical data | |
| Formula | C23H20N2O3S |
| Molar mass | 404.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
[edit ]Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]
Research
[edit ]Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. [2]
References
[edit ]- ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078 . PMID 16740561.
- ^ Anturane Reinfarction Trial Research Group (1980年01月31日). "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.
This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.